Atlas Trials

Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.

Clinical trial NCT03994393 · UNKNOWN

Trial details

NCT number
NCT03994393
Sponsor
University of Sydney
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
EGFR Mutant Advanced Non Small Cell Lung Cancer
Start date
2018-10-23
Primary completion
2023-06-30
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.